Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2408896 | Vaccine | 2007 | 9 Pages |
Abstract
Previous studies with gonadotrophin releasing hormone (GnRH/LHRH) vaccines have shown the usefulness of immunization against this hormone in prostate cancer. To this end, we have generated a completely synthetic peptide modified at position 6 and attached to the 830–844 tetanic toxoid (TT) helper T cell sequence. Through this work we have demonstrated that the GnRHm1-TT molecule was highly immunogenic when it is formulated as an oil-based emulsion adjuvated with Montanide ISA 51. That results correlated directly with testosterone reduction and tumor growth inhibition of the Dunning R3327-H androgen responsive prostate tumor model in rats. GnRHm1-TT, proved to be safe and useful for future clinical trials.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jesús A. Junco, Peter Peschke, Ivan Zuna, Volker Ehemann, Franklin Fuentes, Eddy Bover, Eulogio Pimentel, Roberto Basulto, Osvaldo Reyes, Lesvia Calzada, María D. Castro, Niurka Arteaga, Yovisleidis López, Hilda Garay, Héctor Hernández, Ricardo Bringas,